Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Robson

Showing results (181-190 of 218) with videos related to

Pageof 22
Sort By:
Elife|October 17, 2023
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort studyGayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, et al.
Research Square|February 24, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 FamiliesXin Yang, Goska Leslie, Alicja Doroszuk, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
Cancer Medicine|July 4, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 7, 2011
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, et al.
Plos Genetics|April 2, 2013
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer riskMia M Gaudet, Karoline B Kuchenbaecker, Joseph Vijai, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
Human Molecular Genetics|August 20, 2011
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association ConsortiumJonine D Figueroa, Montserrat Garcia-Closas, Manjeet Humphreys, et al.
Breast Cancer Research : BCR|February 10, 2016
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, et al.
Pageof 22

Showing results (181-190 of 218) with videos related to

Sort By:
Pageof 22
Elife|October 17, 2023
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort studyGayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, et al.
Research Square|February 24, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 FamiliesXin Yang, Goska Leslie, Alicja Doroszuk, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
Cancer Medicine|July 4, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 7, 2011
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, et al.
Plos Genetics|April 2, 2013
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer riskMia M Gaudet, Karoline B Kuchenbaecker, Joseph Vijai, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
Human Molecular Genetics|August 20, 2011
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association ConsortiumJonine D Figueroa, Montserrat Garcia-Closas, Manjeet Humphreys, et al.
Breast Cancer Research : BCR|February 10, 2016
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, et al.
Pageof 22